Similar articles

• The effect of chronic N-dipropylacetamide ("depamide") treatment on plasmatic immunoglobulins of epileptic patients.

  Musolino R, Natoli M, Gallitto G, Morgante L, Serra S, Pisani F, Di Perri R. Musolino R, et al. Acta Neurol (Napoli). 1980 Apr;2(2):115-20. Acta Neurol (Napoli). 1980. PMID: 6771967 No abstract available.
• [Clinical and electroencephalographic study of the effects of valpramide in treating epilepsy].

  Zhou SS. Zhou SS. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1985 Jun;18(3):142-4. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1985. PMID: 3932024 Chinese. No abstract available.
• [Determination of N-Dipropylacetamide serum concentration and its clinical significance in epileptic children].

  Shi FL. Shi FL. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1986 Aug;19(4):217-20. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1986. PMID: 3095059 Chinese. No abstract available.
• [Do results of the recent clinical trials change the place of valproate in treatment of epilepsy?].

  Bosak M. Bosak M. Przegl Lek. 2008;65(11):807-9. Przegl Lek. 2008. PMID: 19205366 Review. Polish.
• New generation of valproic acid.

  Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, Jargiełło M, Czuczwar SJ. Trojnar MK, et al. Pol J Pharmacol. 2004 May-Jun;56(3):283-8. Pol J Pharmacol. 2004. PMID: 15215557 Review.